CB Scientific, Inc. (CBSC) (the “Company”) is pleased to announce that, in connection with the acquisition of the business assets of Prevent Health Care International Corporation, the following changes have been made to the management and board of directors of CBSC.

Charles “Chip” Martin has become the CEO, President and a Director of the Company.

He has held positions in sales, marketing, and executive management in the non-invasive Ambulatory ECG marketplace for more than 35 years. His extensive experience includes working in direct product capital equipment and software sales both domestically and internationally, management and direction of IDTF remote cardiac monitoring services, and oversight of international distributor networks in Europe, Asia, and the Middle East. His career in the cardiac medical market began with Oxford Medical in 1985 where he sold the first “real-time” Holter analysis software system and recording devices offered in the US in a four state Midwest territory.

He was promoted to Eastern Regional Sales Manager for the company in 1987. Career highlights include Regional Sales Manager for Spacelabs (Holter, Ambulatory Blood Pressure), National Sales Manager and Director of Sales for Instromedix (Cardiac Event Monitoring – King of Hearts), VP Sales and Marketing for CardioComm Solutions (GEMS Acquisition ECG Software for Event & Pacer TTM follow-up), and VP of Business Development with Biomedical Systems (IDTF Services, Holter, AEM, MCT). From 2014 to 2018, Chip worked as the Senior Director of Global Sales for BioTelemetry Inc. a widely recognized leading provider of remote cardiac monitoring diagnostic services in the US that is publicly traded on the NASDAQ exchange (BEAT). He held the position of SVP of Sales and Marketing for My-Cardia (USA) Inc. from 2018 to 2019 and was promoted to CEO and President of Prevent Health Care International Corporation in August 2019, assuming the same roles now at CB Scientific, Inc., as well as Director.

Robert Kelley has become the CFO, Vice President and a Director of CBSC.

He has extensive experience with high-growth companies from VC-backed high-technology startups to large public corporations in roles including founder, CTO/VP Engineering, EVP Strategic Marketing, Corporate Development. He has led multiple first-mover product teams developing novel enterprise technologies from high-performance computers, broadband networks, and storage, to enterprise software from manufacturing/ERP, financial/accounting, and data warehousing/BI. His graduate studies and teaching includes Computer Science, Linguistics and Artificial Intelligence, Marketing and Analytics. Rob is a Chartered Financial Analyst (CFA). Rob uses analytics and his technology experience to inform marketing strategy, evaluate emerging technologies, and understand economic value for customers.

James E. Ott has become a Director of CBSC.

He held several senior leadership positions in his twenty-eight-year career in the Ambulatory ECG and Clinical Research Trials arena. Upon earning his Master of Science in Biomedical Engineering at Marquette University in 1991, Jim joined Biomedical System in St. Louis, MO in 1992 as a Product Manager where he coordinated the design, development and marketing efforts of their cardiac diagnostic software platform lines. In this role he facilitated regulatory submissions and regulatory inspection for the product line to include the creation of multiple Original Equipment Manufacturer (OEM) channels with major medical device manufacturers both domestically and internationally. He was promoted in 2000 to President of Biomedical Systems Cardiology Division where he managed all aspects of their Independent Diagnostic Testing Facility (IDTF) to include international direct and distributor capital equipment sales, IDTF cardiology lab staffing, technology, sales and marketing, customer service, and reimbursement and regulatory activities. During this time he managed the design, development, and implementation of the company’s internet based Holter data and report transfer platform (Data Exchange), their internet based Holter analysis platform (MyHolter.com) and their Mobile Cardiac Telemetry (MCT) platform – the TruVue® Wireless ECG Monitoring System. Jim was an integral part of successful US patent submissions and granted approvals for all three of these applications in 2004, 2005 and 2013 where he is listed as one of the inventors.

Zbigniew “Zig” Lambo remains a Director of CBSC.

He has, however, stepped down from his transitional management positions with CBSC but will remain a Director of the Company with responsibility for handling certain regulatory and related matters. He was the founder of CBSC’s original predecessor company in 1987 and was involved in taking it public in 1996 as Net:X America Inc., its subsequent transition to CB Scientific, Inc. in 2016 and the acquisition and integration of the assets and business plans of Prevent Health Care International Corporation in 2020.

Source